Aligos Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
Aligos Therapeutics, Inc. carries a market capitalization of 38.43M, placing it among publicly traded companies globally. Its enterprise value stands at 9.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 38.43M |
| Enterprise Value | 9.11M |
Share Statistics
Aligos Therapeutics, Inc. currently has 6.24M shares outstanding.
| Shares Outstanding | 6.24M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.90, and the price-to-book ratio stands at 1.13.
| PE Ratio | N/A |
| PS Ratio | 1.90 |
| PB Ratio | 1.13 |
| P/TBV Ratio | 1.13 |
| P/FCF Ratio | -0.64 |
| P/OCF Ratio | -0.64 |
Enterprise Valuation
| EV / Sales | 0.29 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Aligos Therapeutics, Inc. maintains a current ratio of 2.19, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.19 |
| Quick Ratio | 2.05 |
| Debt / Equity | 10.99 |
| Debt / EBITDA | -0.05 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -113.59 |
| Return on Assets (ROA) | -75.57 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Aligos Therapeutics, Inc. has paid 3.21M in income taxes, reflecting an effective tax rate of 215.07.
| Income Tax | 3.21M |
| Effective Tax Rate | 215.07 |
Stock Price Statistics
Aligos Therapeutics, Inc.'s stock has declined approximately -45.2381% over the past 52 weeks. The 50-day moving average sits at 5.91, while the 200-day moving average is 7.15.
| Beta (5Y) | N/A |
| 52-Week Price Change | -45.2381% |
| 50-Day Moving Average | 5.91 |
| 200-Day Moving Average | 7.15 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Aligos Therapeutics, Inc. generated 31.52M in revenue and converted that into -75.96M in net income, yielding earnings per share of -7.31. EBITDA reached -75.96M, while operating income came in at -78.99M.
| Revenue | 31.52M |
| Gross Profit | N/A |
| Operating Income | -78.99M |
| Pretax Income | -72.75M |
| Net Income | -75.96M |
| EBITDA | -75.96M |
| EBIT | -78.99M |
| Earnings Per Share (EPS) | -7.31 |
Balance Sheet
Aligos Therapeutics, Inc. holds 30.38M in cash and equivalents against 3.50M in total debt, resulting in a net debt position of -30.38M. Total book value stands at 31.88M, with working capital of 33.78M providing operational flexibility.
| Cash & Cash Equivalents | 30.38M |
| Total Debt | 3.50M |
| Net Debt | -30.38M |
| Equity (Book Value) | 31.88M |
| Book Value Per Share | 5.11 |
| Working Capital | 33.78M |
Cash Flow
Aligos Therapeutics, Inc. produced -94.17M in operating cash flow over the past twelve months. After subtracting -355,000.00 in capital expenditures, free cash flow totaled -94.52M - equivalent to -9.09 per share.
| Operating Cash Flow | -94.17M |
| Capital Expenditures | -355,000.00 |
| Free Cash Flow | -94.52M |
| FCF Per Share | -9.09 |
Margins
Aligos Therapeutics, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -250.63 and net profit margin of -241.01 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -250.63 |
| Pretax Margin | -230.81 |
| Profit Margin | -241.01 |
| EBITDA Margin | -241.02 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.63 |
| FCF Yield | -156.38 |
Stock Splits
Aligos Therapeutics, Inc.'s most recent stock split took place on August 19, 2024 with a 25:1 split ratio.
| Last Split Date | 8/19/2024 |
| Split Ratio | 25:1 |
Scores
Aligos Therapeutics, Inc. posts an Altman Z-Score of -16.29, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -16.29 |